Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03431415

Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is disease free survival rate at 5 years in stage IA2 (T1aN0M0 or T1bN0M0 only) non-small cell lung cancer (NSCLC) patients treated either by surgery or stereotactic body radiation therapy (SBRT).

Detailed description

Today, the best medical literature available confirms that surgery is superior to radiation therapy in the treatment of the early stage lung cancer. However, good emerging data demonstrates potential equality between these two treatments. Two major international studies have tried to compare both treatments but have failed to complete the study because of the lack of patients accrual. We chose to design a trial in which patients will be part of a shared decision making process in selecting the treatment modality. Patients with early stage lung cancer, that can undergo surgical treatment will be offered SBRT, and in conjunction with the pulmonologist will decide which treatment they prefer. We intend to complete the recruitment of patients within 02 years, then follow-up for 5 more years to collect data.

Conditions

Interventions

TypeNameDescription
PROCEDUREAnatomical Segmentectomy, Lobectomy or BilobectomyLung Cancer Anatomical Resection
RADIATIONStereotactic Body Radiation TherapySBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.

Timeline

Start date
2018-01-28
Primary completion
2020-03-01
Completion
2025-02-01
First posted
2018-02-13
Last updated
2021-08-24

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT03431415. Inclusion in this directory is not an endorsement.